PMID- 31788992
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2005-0399 (Electronic)
IS  - 2005-0380 (Print)
IS  - 2005-0380 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Jan
TI  - Clinical response and safety of apatinib monotherapy in recurrent, metastatic 
      cervical cancer after failure of chemotherapy: a retrospective study.
PG  - e2
LID - 10.3802/jgo.2020.31.e2 [doi]
LID - e2
AB  - OBJECTIVE: To observe the safety and short-term efficacy of apatinib in the 
      treatment of recurrent, metastatic cervical cancer in patients who have already 
      received more than two kinds of comprehensive treatment. METHODS: Forty-eight 
      patients with recurrent or metastatic cervical cancer after radiotherapy or 
      surgery who received apatinib between June 2016 and June 2017 were involved in 
      this study. These patients experienced progression after first-line or 
      second-line chemotherapy. There were 38 patients with cervical squamous cell 
      carcinoma, 8 with adenocarcinoma, and 2 with adenosquamous carcinoma. 
      Progression-free survival (PFS), overall survival (OS), and treatment-related 
      adverse events (AEs) were reviewed and evaluated. RESULTS: All patients had 
      complete follow-up records, and the median follow-up time was 14.5 months 
      (5.5-20.5 months). Among the 48 patients, 14.58% achieved a partial response and 
      52.08% achieved stable disease. The overall response rate and disease control 
      rate were 14.58% and 66.67%, respectively. The median time that the 48 patients 
      received oral apatinib was 8.2 months. The median PFS was 4.6 months (95% 
      confidence interval [CI]=3.31-5.26) and OS was 13.9 months (95% CI=8.37-17.96). 
      The main apatinib-related adverse reactions were leukopenia (37.5%), neutropenia 
      (41.67%), hemorrhage (37.5%), hypertension (33.33%), proteinuria (12.5%), fatigue 
      (37.5%), and hand-foot syndrome (27.08%). Most of them were grade 1-2, and no 
      drug-related death occurred. CONCLUSIONS: Apatinib can improve the disease 
      control rate of recurrent and metastatic cervical cancer when chemotherapy has 
      failed, and the treatment is well tolerated. This represents that apatinib may be 
      a new treatment option for metastatic cervical cancer patients.
CI  - Copyright (c) 2020. Asian Society of Gynecologic Oncology, Korean Society of 
      Gynecologic Oncology.
FAU - Xiao, Yan
AU  - Xiao Y
AUID- ORCID: 0000-0002-2133-1103
AD  - Department of Gynecologic Oncology, Affiliated Cancer Hospital of Zhengzhou 
      University (Henan Cancer Hospital), Zhengzhou, China.
FAU - Cheng, Huijun
AU  - Cheng H
AUID- ORCID: 0000-0002-4649-8559
AD  - Department of Gynecologic Oncology, Affiliated Cancer Hospital of Zhengzhou 
      University (Henan Cancer Hospital), Zhengzhou, China. chenghuijun66@aliyun.com.
FAU - Wang, Li
AU  - Wang L
AUID- ORCID: 0000-0003-0588-5234
AD  - Department of Gynecologic Oncology, Affiliated Cancer Hospital of Zhengzhou 
      University (Henan Cancer Hospital), Zhengzhou, China.
FAU - Yu, Xiao
AU  - Yu X
AUID- ORCID: 0000-0003-3837-4676
AD  - Department of Gynecologic Oncology, Affiliated Cancer Hospital of Zhengzhou 
      University (Henan Cancer Hospital), Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20190625
PL  - Korea (South)
TA  - J Gynecol Oncol
JT  - Journal of gynecologic oncology
JID - 101483150
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/mortality
MH  - Progression-Free Survival
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Uterine Cervical Neoplasms/*drug therapy/mortality
PMC - PMC6918889
OTO - NOTNLM
OT  - Apatinib Mesylate
OT  - Cervix Neoplasms
OT  - Drug Toxicity
OT  - Molecular Targeted Therapy
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2019/12/04 06:00
MHDA- 2021/03/31 06:00
PMCR- 2020/01/01
CRDT- 2019/12/03 06:00
PHST- 2018/10/20 00:00 [received]
PHST- 2019/04/29 00:00 [revised]
PHST- 2019/05/27 00:00 [accepted]
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
PHST- 2019/12/03 06:00 [entrez]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 31.e2 [pii]
AID - 2020310109 [pii]
AID - 10.3802/jgo.2020.31.e2 [doi]
PST - ppublish
SO  - J Gynecol Oncol. 2020 Jan;31(1):e2. doi: 10.3802/jgo.2020.31.e2. Epub 2019 Jun 
      25.